Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs
Filed with ASX · · 2 pages · English
Story so far
Earlier from Mesoblast
- Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs
- Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure
- First Children To Begin Treatment, Medicaid Covers Ryoncil
- First Three Children to Commence Treatment With Ryoncil®
- Ryoncil Is Now Available For Purchase In The United States
Later from Mesoblast
- Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives
- Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board
- Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025
- FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®
- FDA Provides Ryoncil 7 Years Orphan-Drug Exclusive Approval
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast